Impact of intravenous ferric carboxymaltose on physical performance and patient-reported outcomes in elderly patients with non-dialysis CKD, mild anemia, and iron deficiency: A pilot study

Background: Iron deficiency (ID) is highly prevalent in chronic kidney disease (CKD) and it’s associated with poorer quality of life (QoL) and functional capacity. Intravenous iron therapy is limited to CKD patients with ID and anemia to avoid/delay the need or reduce the dose of erythropoiesis-stimulating agents, according to guidelines. We hypothesized that treatment with IV iron in CKD patients with ID and borderline anemia may improve their physical performance and QoL, independently of its effects on hemoglobin. Methods: Prospective, single-arm study in CKD patients with ID and mild anemia. The 6-min walk test (6-MWT), Piper fatigue scale, Patient’s global assessment (PGA) and QoL (EQ-5D) questionnaires were evaluated at baseline, and at weeks 1 and 4 after receiving IV ferric carboxymaltose. Changes in continuous endpoints and their longitudinal trajectories were estimated with linear mixed regression models (LMRMs). Results: Forty-one patients completed the study. The 6-MWT increased from 296±101 m to 314±106 m at week 1 (p<0.01), and to 325±111 meters at week 4 (p<0.01). PGA, EQ-5D questionnaire and Piper Fatigue scale significantly improved at week 4 from baseline (p<0.05), after adjustement in the last 2 variables. Hemoglobin levels did not increase significantly during the follow-up. Conclusions: IV ferric carboxymaltose (IV FCM) was associated with a significant short-term improvement in the 6-MWT in CKD patients with iron deficiency and mild anemia. PGA, EQ-5D and Piper Fatigue Scale also improved at 4 weeks. These findings suggest a potential short-term benefit of IV ferric carboxymaltose on physical performance and PROMs in this population, independent of hemoglobin changes; however, given the small sample size and absence of a control group, results should be interpreted with caution and considered hypothesis-generating.

Authors

Institutions

Publication Details

Journal
Nefrología
Published
2025-09-22
DOI
https://doi.org/10.1016/j.nefro.2025.501418
Primary Topic
Dialysis and Renal Disease Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of intravenous ferric carboxymaltose on physical performance and patient-reported outcomes in elderly patients with non-dialysis CKD, mild anemia, and iron deficiency: A pilot study

Marco Montomoli, Juan Casas, Elena Giménez-Civera, Julio E. Núñez et al.
Nefrología
Dialysis and Renal Disease Management
article

Impact of intravenous ferric carboxymaltose on physical performance and patient-reported outcomes in elderly patients with non-dialysis CKD, mild anemia, and iron deficiency: A pilot study

Marco Montomoli, Juan Casas, Elena Giménez-Civera, Julio E. Núñez, José Luis Górriz, María Jesús Puchades, Isidro Torregrosa, Aleix Cases, Boris Gonzales, Carlos J. Peña, Miguel González-Rico, Rafael de la Espriella
article en

Abstract

Background: Iron deficiency (ID) is highly prevalent in chronic kidney disease (CKD) and it’s associated with poorer quality of life (QoL) and functional capacity. Intravenous iron therapy is limited to CKD patients with ID and anemia to avoid/delay the need or reduce the dose of erythropoiesis-stimulating agents, according to guidelines. We hypothesized that treatment with IV iron in CKD patients with ID and borderline anemia may improve their physical performance and QoL, independently of its effects on hemoglobin. Methods: Prospective, single-arm study in CKD patients with ID and mild anemia. The 6-min walk test (6-MWT), Piper fatigue scale, Patient’s global assessment (PGA) and QoL (EQ-5D) questionnaires were evaluated at baseline, and at weeks 1 and 4 after receiving IV ferric carboxymaltose. Changes in continuous endpoints and their longitudinal trajectories were estimated with linear mixed regression models (LMRMs). Results: Forty-one patients completed the study. The 6-MWT increased from 296±101 m to 314±106 m at week 1 (p<0.01), and to 325±111 meters at week 4 (p<0.01). PGA, EQ-5D questionnaire and Piper Fatigue scale significantly improved at week 4 from baseline (p<0.05), after adjustement in the last 2 variables. Hemoglobin levels did not increase significantly during the follow-up. Conclusions: IV ferric carboxymaltose (IV FCM) was associated with a significant short-term improvement in the 6-MWT in CKD patients with iron deficiency and mild anemia. PGA, EQ-5D and Piper Fatigue Scale also improved at 4 weeks. These findings suggest a potential short-term benefit of IV ferric carboxymaltose on physical performance and PROMs in this population, independent of hemoglobin changes; however, given the small sample size and absence of a control group, results should be interpreted with caution and considered hypothesis-generating.

NefrologíaVol. 46(2)
UF Health Shands Hospital (US), Universitat de València (ES), Hospital Clínico Universitario de Valencia (ES), INCLIVA Health Research Institute (ES)
Openalex Percentile: Top 73%
Dialysis and Renal Disease Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.